Symbols

ATXS

Astria Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 3

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

EPS Beats Expectation

RSI Overbought

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATXS

Astria Therapeutics, Inc.

A company that develops novel therapeutics for the rare and niche allergic and immunological diseases

Industry

Pharmaceutical

Established Date

06/26/2008

Listing Date

06/25/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.astriatx.com

Security Type

Common stock

Office address

75 State Street, Suite 1400, Boston, Massachusetts 02109

Business

Introduction

Astria Therapeutics, Inc., was founded in Delaware on June 26, 2008 and is headquartered in Cambridge, Massachusetts. The company is a biopharmaceutical company focused on the discovery, development and commercialization of new therapies. The company's mission is to bring hope to patients and families affected by rare and niche allergic and immune diseases through life-changing therapies. The company's lead product candidate is STAR-0215, a potentially best-in-class monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. Based on the data generated so far and the existing HAE treatment profile, STAR-0215 has the potential to be the most patient-friendly chronic treatment for HAE.

Company Financials

EPS

ATXS has released its 2025 Q3 earnings. EPS was reported at -0.55, versus the expected -0.42, missing expectations. The chart below visualizes how ATXS has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ATXS has released its 2025 Q3 earnings report, with revenue of 706.00K, reflecting a YoY change of NaN%, and net profit of -31.64M, showing a YoY change of -28.98%. The Sankey diagram below clearly presents ATXS's revenue sources and cost distribution.